PA
BATRK icon

PharVision Advisers’s Atlanta Braves Holdings Series B BATRK Stock Holding History

PharVision Advisers’s Portfolio BATRK Stock Details BATRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,360
Closed -$348K – 708
2025
Q3 		$348K Buy
+8,360
New +$369K 0.2% 142

Other funds holding BATRK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HRCM
Hawk Ridge Capital Management Los Angeles, California $2.75B AUM 20.09% 1-Year Est. Return
BBCM
Broad Bay Capital Management New York $1.18B AUM 65.45% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
CI Investments Inc
CI Investments Inc Toronto, Ontario, Canada $20.6B AUM 29.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's BATRK Position: Q4 2025 in Review

PharVision Advisers sold out of Atlanta Braves Holdings Series B (BATRK) in Q4 2025, closing a stake of 8,360 shares — an estimated $348K sold.

PharVision Advisers first reported a position in BATRK in Q3 2025 and held it in 1 quarter. The position peaked at $348K in Q3 2025. 286 funds tracked by Wall St. Rank hold BATRK as of Q4 2025.

  • PharVision Advisers reported no remaining Atlanta Braves Holdings Series B position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 8,360 Atlanta Braves Holdings Series B shares in Q4 2025, an estimated $348K.
  • PharVision Advisers first reported a position in Atlanta Braves Holdings Series B in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Atlanta Braves Holdings Series B position peaked at $348K in Q3 2025.
  • 286 funds tracked by Wall St. Rank held Atlanta Braves Holdings Series B as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.